Physiomics and Bayer launch a new Service

Physiomics and Bayer Technology Services sign UK distribution agreement for PK-Sim®

Oxford, UK and Leverkusen, Germany 23rd June 2005 Physiomics (AIM: PYC) and Bayer Technology Services GmbH (BTS) have signed an agreement under which BTS has appointed Physiomics as a distributor of its PK-Sim® pharmacokinetic modelling products and services
for a renewable five-year period. The agreement, which covers all therapeutic areas, should also enable increased sales of the Clinical Response Prediction system, which combines PK-Sim with Physiomics’ pharmacodynamic SystemCell® technology.

Physiomics and BTS believe that advanced whole body simulations can optimise the transition from preclinical to clinical development and help in the optimisation of dose scheduling, one of the major problems in clinical trial design. Studies1 have shown that improving the drug development success rate by 10% overall could save $242m per drug. Under a separate global deal announced in September 2004, Physiomics and Bayer
collaborate on Clinical Response Prediction in the area of cancer.

Physiomics will initially develop the UK market for PK-Sim and act as the primary customer interface. Financial terms of the agreement were not disclosed.

Dr Stephen Parker, Chairman of Physiomics, commented: “We are delighted to further our relationship with Bayer. This is an important achievement for the Company as it extends and diversifies our product base and range of business development opportunities. The new distributor agreement will enable us to work on all therapeutic areas with a very sophisticated service and product offering, and should have a positive impact on Clinical
Response Prediction sales.”

1Tufts Center Impact Report 2002

For further information please contact:


Physiomics plc

Dr Stephen Parker (Chairman)              Tel: 07771 526 785
Dr John Savin (CEO)                       Tel: 01865 784 980

Northbank Communications                  Tel: 020 7886 8150

Emma Palmer
Fiona Brown
Rowan Minnion

Notes to Editors

Physiomics plc

Physiomics plc, founded in 2001, develops and sells services aimed at reducing the high cost of drug development for pharmaceutical and biotechnology companies by optimising the design of cancer clinical trials through the application of computer-based simulations. Physiomics is also applying its technologies to develop proprietary cancer therapy products for out-licensing and, to this end, it has secured an option to license two innovative molecules. For more information go to www.physiomics-plc.com

SystemCell is a registered trademark of Physiomics plc

Bayer Technology Services GmbH

Bayer Technology Services GmbH is the center for technological competence of the Bayer Group worldwide. The Bayer company employs more than 2,100 experts worldwide at its  headquarters in Leverkusen and other German locations, as well as in regional offices in Baytown (Texas, USA), Antwerp (Belgium), Mexico City (Mexico) and Shanghai (Peoples Republic of China). Bayer Technology Services posted sales of EUR 520 million in 2004, including utilities procurement for all Bayer sites in Germany (first six month only). In addition to fully-integrated solutions along the life cycle of pharmaceutical and chemical plants – from development through engineering and construction to process optimization, Bayer Technology Services offers a broad range of products and services for all stages of diagnostics and drug research and development. Examples include nano-phosphors, the pharmacokinetic simulation software PK-Sim® as well as sophisticated data mining and modeling techniques. Additional information about Bayer Technology Services is available at www.bayertechnology.com.

PK-Sim is a registered trademark of Bayer Technology Services GmbH

 

})(jQuery)